Renaissance Capital logo

PRLD News

US IPO Weekly Recap: Health and tech dominate the calendar in an 11 IPO week

GDRX

September activity remained high as 11 IPOs and eight SPACs went public this past week. The IPO market shows no signs of slowing with eight IPOs and 18 SPACS submitting initial filings. Prescription drug price comparison platform GoodRx...read more

Cancer biotech Prelude Therapeutics prices IPO at $19, the high end of the range

Prelude Therapeutics logo

Prelude Therapeutics, a Phase 1 biotech developing PRMT5 inhibitors for difficult to treat cancers, raised $158 million by offering 8.3 million shares at $19, the high end of the range of $17 to $19. The Wilmington, DE-based company plans to list on the...read more

Oncology biotech Prelude Therapeutics sets terms for $150 million IPO

Prelude Therapeutics logo

Prelude Therapeutics, a phase 1 biotech developing small molecule therapies for cancer, announced terms for its IPO on Monday. The Wilmington, DE-based company plans to raise $150 million by offering 8.3 million shares at a price range of $17 to $19. At the...read more

US IPO Weekly Recap: The September IPO market kicks off with a quiet week

CMLFU

While there were no IPOs this past week, five SPACs went public ahead of the post-Labor Day rush. Casdin Capital and Corvex Management’s SPAC CM Life Sciences (CMLFU) upsized to raise $385 million. Led by the firms’ founders,...read more